Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Clinical trial NCT05171660 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05171660
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-08
- Primary completion
- 2026-12-30
- Enrollment
- 446
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.